Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure
Ten trials 13,14,2632 had sufficient data for the meta-analysis (n=366 treatment, n=359 control), and five trials 15,26,3335 were excluded from quantitative synthesis due to incomplete or non-extractable data
GLP-1s, of course, have a dramatic effect on lowering blood sugar in their own right
Standard protocol: Cycle length: 34 weeks on, 4 weeks off minimum Some protocols: 21 days on, 4 weeks off (the "21-day cycle") More conservative: 2 weeks on, 4 weeks off Use the off-weeks to let receptor density recover
By: Kristin Brooks Managing Editor, Contract Pharma For pharma manufacturers, the growth of GLP-1 drugs to treat conditions such as diabetes and obesity has placed increased strain on the supply chain and subsequent pressure to avoid bottle necks
TRANSCEND-T2D-1 is a phase 3 diabetes trial, and its 2026 data reported significant A1C and weight reductions at 40 weeks [8], [9]